Press Release

October 29, 2026 National Stock Exchange of India Limited BSE Limited Plot No. C/1, “G” Block, Exchange Plaza, Phiroze Jeejeebhoy Towers, Bandra Kurla Complex, Bandra (East), Dalal Street, Mumbai 400 051 Mumbai 400 001 Symbol: RPGLIFE Security Code: 532983 Dear Sirs /Madam, Sub: Press Release - Financial Results Please find enclosed herewith a copy of press release with respect to unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026. Kindly take the above on record. Thanking you, Yours Sincerely, For RPG Life Sciences Limited Rajesh Shirambekar Head- Legal & Company Secretary Encl: as above Q2 FY27: Revenue grows 16.5% with a healthy adjusted EBITDA profile of 23.7% Mumbai, 29 October 2026: RPG Life Sciences Limited today announced its financial results for H1 and the quarter ended on 30th September, 2026. Key performance highlights  Revenue from Operations grew 16.5% to ₹211.6 crore, unlocking the ₹200 crore quarterly revenue milestone  Robust gross margin expansion by 260 bps in Q2 despite challenging external environment  Highest-ever Adjusted EBITDA (excluding one-off API acquisition and restructuring costs of ₹5.5 crore) grew 15% to ₹50.1 crore to record a 23.7% EBITDA (v/s 24.0% y-o-y); in line with revenue growth  Our Domestic Formulations business sustained its market-beating trajectory in FY27, becoming the 4th fastest growing company in IPM and achieving “Top 50” rank  Our flagship brand, Naprosyn crosses ₹100 cr. sales milestone Particulars Y-o-Y Revenue from Operations Growth Q2 FY27 Revenue ₹211.6 crores in Q2 FY27 v/s ₹181.7 crores in Q2 FY26 16.5% H1 FY27 Revenue ₹407.3 crores in H1 FY27 v/s ₹350.6 crores in Q2 FY26 16.2% Q2 FY27 Adjusted EBITDA* ₹50.1 crores in Q2 FY27 v/s ₹43.6 crores in Q2 FY26 15.0% H1 FY27 Adjusted EBITDA* ₹97.9 crores in H1 FY27 v/s ₹84.3 crores in Q2 FY26 16.1% * Excludes one-off API acquisition and restructuring costs of ₹5.5 crore RPG Life Sciences sustained strong growth momentum in Q2 crossing the ₹200 crore quarterly revenue milestone. Revenue from Operations grew 16.5% to ₹211.6 crore. The acquired sites contributed ₹0.5 crore in Q2 and full revenue contribution from both sites will commence from Q3 onwards, owing to transaction closure in end-September. Along with strong revenue growth, gross margin also expanded by 260 bps in Q2 despite a challenging external environment and industry tailwinds. Q2 Adjusted EBITDA grew 15.0% to ₹50.1 crore (Reported EBITDA considering the impact of the abovementioned one-offs is ₹44.7 crore). Also, adjusted PBT before the above one-offs grew by 11.3%, supported by topline growth, strategic initiatives and operating discipline. Domestic Formulations continued to outperform the market in FY27, led by strong volume growth and performance across specialty therapies. RPG Life Sciences achieved 11.6% growth and became the 4th fastest-growing pharmaceutical company in IPM, entering ‘Top 50’ IPM ranking*. International Formulations revived its growth trajectory, growing at 6.4% in Q2 and 7.0% in H1, supported by growth across key products and markets. The business is building its next phase of growth through new market registrations, CDMO opportunities, focused business development and cost-competitive initiatives. API business organically delivered a strong quarter with ₹27.5 crore sale in Q2 and ₹54.1 crore sale in H1. What’s important to note is that the API business saw significant expansion during the quarter. RPGLS transferred its API business to RPG Active Pharma, onboarded InvAscent, healthcare and life sciences focused PE firm, as a strategic investor, and completed the acquisitions of 2 API plants - Actis Generics and Raghava Lifesciences. The expanded network has five times the manufacturing capacity, four times the reactors, three times the products and pipeline molecules, and twice the customer and employee base. Commenting on the results and business outlook, Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., said: “We have delivered another strong quarter with 16.5% revenue growth and 15% adjusted EBITDA growth, while maintaining healthy margins despite external cost pressures. More importantly, the quality of growth remains strong. Domestic Formulations continues to outperform the market, supported by volume growth, specialty therapies and new launches, while our API base business recorded significant growth during the quarter. The creation of RPG Active Pharma and the acquisitions of Actis and Raghava mark an important step in our API strategy. With the transactions completed, our focus is now on integration and value creation through higher asset utilization, deeper customer engagement, international expansion, and cost improvement. Going forward, we will continue to strengthen Domestic Formulations, build a more competitive International Formulations business, and systematically scale the expanded API business. These priorities give us a clear path to sustained and profitable growth.” *Source: Pharmarack MAT September 2026 Database RPG Life Sciences Ltd (www.rpglifesciences.com) RPG Life Sciences is an integrated research-based pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company produces a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients. RPG Group (www.rpggroup.com) RPG Group, established in 1979, is one of India’s fastest-growing business groups with a turnover of US$ 5.2 billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses. Media Contact Rashmi Menon – 88980 20577 | rashmi@rpg.in